trending Market Intelligence /marketintelligence/en/news-insights/trending/uUKcde-5YcRBUdIpyFh-Lw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Vertex drug cuts pain in mid-stage trial, gets US FDA breakthrough tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Vertex drug cuts pain in mid-stage trial, gets US FDA breakthrough tag

Boston's Vertex Pharmaceuticals Inc. said VX-150 delivered statistically significant and clinically meaningful pain reduction in a mid-stage study, meeting its main goal.

The six-week phase 2 trial enrolled patients with small fiber neuropathy, a condition in which narrow nerve fibers outside the brain and spinal cord are damaged, causing pain, burning and tingling.

Vertex said 46 patients received VX-150 and 43 patients received placebo, 91% and 81% of whom completed treatment, respectively.

The study measured patients' daily pain intensity on an 11-point scale and computed their weekly average: 6.43 in the VX-150 group and 5.99 in the placebo group. After six weeks of treatment, VX-150 reduced the rating by 2.02, while placebo only reduced it by 0.93.

Additionally, VX-150 was generally well-tolerated in the trial. Adverse events in the study were mostly mild or moderate, occurring in 63% of the VX-150 group and in 56% of the placebo group, according to Vertex.

The trial is Vertex's third positive proof-of-concept study for VX-150, the other two being for chronic pain due to osteoarthritis, and after bunionectomy surgery, which is still ongoing.

Separately, the U.S. Food and Drug Administration granted VX-150 breakthrough-therapy status for moderate to severe acute pain. The designation expedites the development and review of drugs meant to treat serious conditions.

VX-150 inhibits the NaV1.8 protein, which is found in certain neurons, to block signals of pain.